New liposomal drug shows promise for Hard-to-Treat cancers

NCT ID NCT03207672

Ongoing Disease control Sponsor: Eisai Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug called E7389 liposomal formulation in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. The study also looks at how the drug works in specific cancers like breast cancer, adenoid cystic carcinoma, and small cell lung cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenoid cystic carcinoma breast cancer esophageal cancer gastric cancer neoplasm small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Eisai Trial Site 1

Chuo-ku, Tokyo, Japan
Eisai Trial Site 10

Hidaka, Saitama, Japan
Eisai Trial Site 11

Kyoto, Japan
Eisai Trial Site 12

Fukuoka, Japan
Eisai Trial Site 2

Osaka, Japan
Eisai Trial Site 3

Kashiwa, Chiba, Japan
Eisai Trial Site 4

Koto-ku, Tokyo, Japan
Eisai Trial Site 5

Sapporo, Hokkaido, Japan
Eisai Trial Site 6

Yokohama, Kanagawa, Japan
Eisai Trial Site 7

Shinjuku-ku, Tokyo, Japan
Eisai Trial Site 8

Nishinomiya, Hyōgo, Japan
Eisai Trial Site 9

Bunkyo-ku, Tokyo, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.